September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
Topical Fosaprepitant Treatment in Established Corneal Neovascularization
Author Affiliations & Notes
  • Fabio Bignami
    Cornea and Ocular Surface Disease Unit, Eye Repair Lab, IRCCS San Raffaele Scientific Institute, Milan, Italy
  • Anna Lorusso
    Cornea and Ocular Surface Disease Unit, Eye Repair Lab, IRCCS San Raffaele Scientific Institute, Milan, Italy
  • Paolo Rama
    Cornea and Ocular Surface Disease Unit, Eye Repair Lab, IRCCS San Raffaele Scientific Institute, Milan, Italy
  • Giulio Ferrari
    Cornea and Ocular Surface Disease Unit, Eye Repair Lab, IRCCS San Raffaele Scientific Institute, Milan, Italy
  • Footnotes
    Commercial Relationships   Fabio Bignami, None; Anna Lorusso, None; Paolo Rama, None; Giulio Ferrari, Giulio Ferrari (P)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 3518. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Fabio Bignami, Anna Lorusso, Paolo Rama, Giulio Ferrari; Topical Fosaprepitant Treatment in Established Corneal Neovascularization. Invest. Ophthalmol. Vis. Sci. 2016;57(12):3518.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Corneal avascularity is important for a clear vision. Preexisting corneal stromal vessels are a strong risk factor for immune rejection after corneal transplantation. Available medical therapies for established corneal neovascularization (CNV) are poorly effective and associated with significant side effects.
The activation of neurokinin-1 receptor (NK-1R) through its ligand Substance P promotes ocular inflammation and CNV.
We tested the safety and efficacy of topical NK-1R antagonist Fosaprepitant in the treatment of animal model with established CNV.

Methods : Twenty alkali burned C57BL/6 mice received Fosaprepitant 10 mg/mL, topically 6 times a day in the right eye for 10 days. A second group was treated with normal saline, as control. The treatment was started 7 days after corneal injury, when CNV was established. Ten healthy mice received the same topical treatment for 10 days to evaluate Fosaprepitant safety. Hemangiogenesis and lymphangiogenesis were automatically measured by means of VesselJ plugin (ImageJ). Leukocyte infiltration and secondary outcome measures, such as opacity and corneal fluorescein, were evaluated.
Differences between groups were assessed using unpaired t-test or Mann-Whitney U test, as appropriate.

Results : Topical Fosaprepitant administration induced a significant reduction of (i) CD31+ blood corneal neovessels (-27%, P = 0.0132), (ii) LYVE1+ lymphatic corneal neovessels (-31%, P = 0.0118), and (iii) CD45+ leukocyte infiltration (-36%; P = 0.0237). Moreover, Fosaprepitant-treated corneas showed a reduction in opacity and corneal fluorescein staining, suggesting reduced inflammation. Finally, topical Fosaprepitant resulted safe on ocular surface: no signs of hyperemia/conjunctivitis, opacity, perforations or epithelial defects were detected.

Conclusions : All these data suggest that NK-1R antagonist, such as Fosaprepitant, could be a new promising therapeutic tool to induce regression of established CNV.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×